M Bio Technology Inc. is a leading company specializing in the development of diagnostics, therapeutics, and vaccines for mycoplasma infections. With locations in Tokyo and Chiba, they are committed to advancing medical treatments and preventive measures for mycoplasma-related diseases.

Established in January 2005, M Bio Technology Inc. has a strong track record of success. They have collaborated with prestigious organizations such as Chiba University and the Bioinformatics Research Center to conduct groundbreaking research projects. In 2018, they received the New Value Creation Award, recognizing their innovative contributions to the industry.

The company's management team, led by President and CEO Kazuhiro Matsuda, is dedicated to driving advancements in the field. They have also formed partnerships with major pharmaceutical companies for joint research and development initiatives.

M Bio Technology Inc. is actively involved in global expansion, propelled by their inclusion in JETRO's "New Export Power Consortium." Their expertise extends to various medical applications, including rare neurological diseases caused by mycoplasma infection.

Through their cutting-edge technology and commitment to research, M Bio Technology Inc. is revolutionizing the landscape of mycoplasma infections and contributing to the advancement of medical science. Contact them today to learn more about their innovative solutions.